Eficácia e Segurança a Longo Prazo de Baricitinib com e sem Metotrexato para o Tratamento de Artrite Reumatoide: Experiência com a Continuação de Baricitinib Monoterapia ou Depois de Troca de Metotrexato Monoterapia ou Baricitinib mais Metotrexato
Arthritis Care Res (Hoboken) 2020;72(8):1112-1121
This 24-week update from the baricitinib RA-BEYOND LTE study follows patients previously treated in the pivotal study RA-BEGIN. It demonstrates the maintained safety and efficacy of baricitinib monotherapy, and the effects of concurrent MTX treatment on response rates and patient reported outcomes. Previous P3 study RA-BEGIN demonstrated the superior efficacy of 4mg baricitinib compared to MTX monotherapy up to 52 weeks, with no major safety events being identified. At the end of the trial, pati...